Multi-Center PAMPA Study

Psoriasis Clinical Trial

— PAMPA  

Official title:

Preventing Arthritis in a Multi-Center Psoriasis At-Risk Cohort

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05004727
• Other study ID #: 20-01158
• Status: Recruiting
• Phase: Phase 4
• Start date: February 16, 2022
• Est. completion date: March 1, 2026

Study information

• Verified date: January 2024
• Source: NYU Langone Health
• Contact: Jose Scher, MD
• Phone: 6465017400
• Email: Jose.Scher[@]nyulangone.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multi-center (North-America), randomized, double-blind, placebo-controlled, wait-list, interventional, preventive trial of guselkumab in high-risk psoriasis patients compared to non-biologic standard of care. The primary objective of our proposed trial will be to test the hypothesis that a prolonged, unresolved skin inflammation coupled with musculoskeletal power-doppler ultrasound (MSKPDUS) abnormalities driven by IL-23 increase the risk for transition into PsA and that an intervention that targets one of these pivotal molecules (i.e., Guselkumab) will: 1. Diminish MSKPDUS findings at 24 weeks, and 2. Significantly reduce or prevent the emergence of synovio-enthesial phenotype at year 2.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 350
• Est. completion date: March 1, 2026
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. 18 years old or older;

2. Both male & female;

3. Psoriasis diagnosis (per dermatologist) for at least 2 years (in at least 30% of participants);

4. Willing and able to provide informed consent;

5. Fulfillment of HR-PsO criteria (Psoriasis (PsO) patients will meet the definition of HR if they fulfill the following criteria: a) PsO duration >2 years and Psoriasis Body Surface Area (BSA) >3% and positive imaging findings in MSKPDUS defined as a RM-PsASon score of >3.36

Exclusion Criteria:

1. Evidence of inflammatory joint pain, enthesitis and/or dactylitis on exam;

2. Current systemic immunosuppressive medication use (i.e., methotrexate, apremilast) at the time of enrollment or biologic therapy (ever);

3. RA seropositivity (mid-high RF/ACPA titers);

4. Current active malignancy;

5. History of symptomatic polyarticular OA or other joint conditions (such as RA, gout, etc) that may impair the ability to assess for PsA development

6. Conditions where initiation of guselkumab is prohibited in the prescribing information, including clinically important active infection and untreated latent tuberculosis;

7. Known hypersensitivity to the study agent.

Related Conditions & MeSH terms

• Psoriasis

Intervention

Drug:
• Guselkumab
Guselkumab 100 mg 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (month 0 to month 24 for arm 1; week 24 to month 24 for arm 2).
• Placebo
• Placebo to Guselkumab 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (Month 0 to Week 20 for Arm 2).

Locations

Country	Name	City	State
Canada	Memorial University	Saint John's	Newfoundland and Labrador
Canada	Women's College Research Institute, University of Toronto	Toronto	Ontario
United States	Brigham and Women's Hospital	Boston	Massachusetts
United States	NYU Langone Health	New York	New York
United States	University of Rochester Medical Center (URMC)	Rochester	New York

Sponsors (2)

Lead Sponsor	Collaborator
NYU Langone Health	Janssen Scientific Affairs, LLC

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Musculoskeletal, Power Doppler Ultrasound (MSK-PDUS) Composite Score	Score is defined by the ultrasound (General Electric Logiq E9 or E10) equipment, not calculated through a scale.	Baseline, Week 24
Primary	Percentage of Patients Transitioning to Psoriatic Arthritis (PsA) by Modified CASPAR Criteria at Year 2	To meet CASPAR criteria for diagnosis of PsA, a participant must have inflammatory articular disease (joint, spine, entheseal or dactyitic) and at least 3 points from the following: Evidence of current psoriasis (2pts), personal history of psoriasis (2pts), family history (1pt); Typical psoriatic nail dystrophy including onycholysis, pitting, and hyperkeratosis observed on current physical examination (1pt); A negative test result for the presence of rheumatoid factor by any method except latex (1pt); Either current dactylitis, defined as swelling of an entire digit, or a history of dactylitis recorded by a rheumatologist (1pt); Radiographic evidence of juxta-articular new bone formation appearing as ill-defined ossification near joint margins (but excluding osteophyte formation) on plain radiographs of the hand or foot (1pt) The eCRF will autopopulate the total number of points. If the total score = 3, the participant meets criteria for PsA diagnosis.	Year 2
Secondary	Percentage of Patients Transitioning to Psoriatic Arthritis (PsA) by Modified CASPAR Criteria at Year 1	To meet CASPAR criteria for diagnosis of PsA, a participant must have inflammatory articular disease (joint, spine, entheseal or dactyitic) and at least 3 points from the following: Evidence of current psoriasis (2pts), personal history of psoriasis (2pts), family history (1pt); Typical psoriatic nail dystrophy including onycholysis, pitting, and hyperkeratosis observed on current physical examination (1pt); A negative test result for the presence of rheumatoid factor by any method except latex (1pt); Either current dactylitis, defined as swelling of an entire digit, or a history of dactylitis recorded by a rheumatologist (1pt); Radiographic evidence of juxta-articular new bone formation appearing as ill-defined ossification near joint margins (but excluding osteophyte formation) on plain radiographs of the hand or foot (1pt) The eCRF will autopopulate the total number of points. If the total score = 3, the participant meets criteria for PsA diagnosis.	Year 1
Secondary	Severity of PsA at the time of synovio-entheseal development	Severity will be categorized as mild, moderate, or severe.	Year 2
Secondary	Change in the ultrasound composite score of synovitis	Graded from 0-3 as absent, mild, moderate or severe according to images of a reference atlas (Hammer HB 2011). PD signal: 0=no PD-signal, 1=up to three single or two confluent signals, 2=less than half of the visible intracapsular area and 3=half or more of the visible intracapsular area covered by PD-signals.	Baseline, week 24
Secondary	Change in Madrid Sonographic Enthesis Index (MASEI) Score	MASEI: Structure is considered pathological (score=1) if there is a loss of fibrillar pattern, hypoechoic aspect, or fusiform thickening of the entheses. Erosions are defined as a cortical breakage with a step-down contour defect at the attachment of entheses at bone and graded with 0=absent or 3=present. Fascia and tendon thickness are measured at the point of maximal thickness on the bony insertion and graded with 0=normal or 1=thickened according to the reference values of the MASEI index. Enthesophytes are defined as calcifications at the entheses insertions into bone and graded with 0=absent, 1=small calcification, 2=clear presence of enthesophyte/calcification, 3= large calcifications or ossifications. PD-signals within entheses are scored with 0=absent or 3=present. Bursitis is investigated at the level of distal patellar tendon (infrapatellar bursitis) and the level of Achilles tendon insertion (retrocalcaneal bursitis) and graded with 0=absent and 1=present.	Baseline, week 24
Secondary	Psoriasis Body Surface Area (BSA)	The total BSA affected by plaque-type psoriasis will be estimated from the percentages of areas affected, including head, trunk, upper limbs and lower limbs. The following calculations will be done: each reported percentage will be multiplied by its respective body region corresponding factor (head = 0.1, trunk = 0.3, upper limbs = 0.2, lower limbs = 0.4). The resulting four percentages will be added up to estimate the total BSA affected by psoriasis.	Week 24
Secondary	Achieved IGA mod 2011 Score	Score 0 - Clear - No signs of psoriasis. Post-inflammatory hyperpigmentation may be present Score 1 - Almost clear - Normal to pink coloration of lesions; no thickening; no to minimal focal scaling Score 2 - Mild disease - Pink to light red coloration; just detectable to mild thickening; predominantly fine scaling Score 3 - Moderate disease - Dull bright red, clearly distinguishable erythema; clearly distinguishable to moderate thickening; moderate scaling Score 4 - Severe disease - Bright to deep dark red coloration; severe thickening with hard edges; severe / coarse scaling covering almost all or all lesions	Week 24
Secondary	Change in Functional Assessment of Chronic Illness Therapy (FACIT) Scale	FACIT consists of 13 statements regarding fatigue (e.g., "I feel fatigued", "I feel weak all over", "I feel tired", etc.). Items are scored as follows: 4=not at all, 3=a little bit, 2=somewhat, 1=quite a bit; 0=very much, EXCEPT items #7 and 8 which are reversed scored. Total score range is 0-52. A score of less than 30 indicates severe fatigue. The higher the score, the better the quality of life.	Week 24
Secondary	Change in EuroQol-5D (EQ-5D) Score	The scale measures how good or bad one's health is on the day of the questionnaire. Total score is 0-100; the higher the score, the better the health (0 = worst health one can imagine, 100 = best health one can imagine)	Baseline, Week 24
Secondary	Change in EuroQol-5D (EQ-5D) Score	The scale measures how good or bad one's health is on the day of the questionnaire. Total score is 0-100; the higher the score, the better the health (0 = worst health one can imagine, 100 = best health one can imagine)	Baseline, Year 2
Secondary	Change in International Dermatology Outcome Measures - Musculoskeletal -8 (IDEOM-MSK-8) Score	IDEOM-MSK-8 is a short questionnaire that allows people with MSK conditions to report their symptoms and quality of life in a standardized way. The total range of score is 0-56; the higher the score, the better the MSK health status. In order to calculate the total score, the numbers next to the boxes that the participant has ticked on the questionnaire form is added up.	Baseline, Week 24
Secondary	Change in Ultrasound Score	Score is defined by the ultrasound (General Electric Logiq E9 or E10) equipment, not calculated through a scale.	Baseline, Week 24